---
title: "AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300551134.md"
description: "AbbVie has initiated a Phase 2 trial for ABBV-295, an amylin analog discovered by Gubra, targeting adults with overweight or obesity. The launch follows favorable Phase 1 results presented at EASD 2026, which demonstrated meaningful weight loss and good tolerability. These findings support the potential for less frequent dosing, differentiating ABBV-295 from incretin-based therapies."
datetime: "2026-09-30T09:51:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300551134.md)
  - [en](https://longbridge.com/en/news/300551134.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300551134.md)
generator: "portal-rs"
---

# AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295

-   Gubra flagged AbbVie’s detailed Phase 1 results for obesity candidate ABBV-295, presented at EASD 2026 in Milan. \* Data showed meaningful weight loss across dosing schedules, supporting continued development of the long-acting amylin program. \* Tolerability looked favorable, with side effects mainly mild and concentrated early in treatment. \* Findings supported less frequent dosing potential, strengthening differentiation from incretin-based weight-loss drugs. \* A Phase 2 trial in adults with overweight or obesity started in August 2026 under AbbVie’s lead. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates](https://longbridge.com/en/news/300591646.md)
- [AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo | ABBV Stock News](https://longbridge.com/en/news/300695604.md)
- [AbbVie wins EU approval for paediatric pJIA use](https://longbridge.com/en/news/300559910.md)
- [BUZZ-Genmab at 3-year high after blood cancer drug combination study results](https://longbridge.com/en/news/301001061.md)
- [FDA approves AbbVie’s JUVMO for adults with Parkinson’s disease](https://longbridge.com/en/news/300301299.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**